Filing Details
- Accession Number:
- 0001209191-16-142355
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-09-21 21:28:19
- Reporting Period:
- 2016-09-19
- Filing Date:
- 2016-09-21
- Accepted Time:
- 2016-09-21 21:28:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 873303 | Sarepta Therapeutics Inc. | SRPT | Pharmaceutical Preparations (2834) | 930797222 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1529297 | T David Howton | 215 First Street, Suite 415 Cambridge MA 02142 | Svp, General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-09-19 | 8,000 | $13.90 | 11,168 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-09-19 | 8,000 | $50.00 | 3,168 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2016-09-19 | 464 | $0.00 | 3,632 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2016-09-19 | 19,125 | $0.00 | 22,757 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2016-09-19 | 1,304 | $50.00 | 21,453 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Options (right to buy) | Disposition | 2016-09-19 | 8,000 | $13.90 | 8,000 | $13.90 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 72,007 | 2016-02-27 | 2025-02-27 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction.
- 100% of the Restricted Stock Award ("RSA") granted on September 19, 2016 vests six months from the date of grant. The Company will withhold the shares to satisfy the executive's tax obligation upon vesting.
- 15,300 RSAs vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, with an additional 3,825 RSAs vesting during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million. The Company will withhold the shares to satisfy the executive's tax obligation upon vesting.
Billionaire Hedge Funds
